Background Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Serum uric acid (SUA), a product of ...

Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

[19] As for the other nonprimary outcome measures, perindopril did show some benefit in improving NYHA class, decreasing heart failure hospital admission at 1 year, and increasing the 6-minute ...

Findings from the TAVR UNLOAD study found limited benefits of transcatheter aortic valve replacement (TAVR) in the treatment ...

Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company dedicated to interventional treatment for structural heart diseases with TTVR ...

NYHA class III/IV Dilated (ischemic or idiopathic) cardiomyopathy Sinus rhythm >/= 55 bpm QRS >/= 120 ms PR interval >/= 150 ms ...

Congestion is a common symptom of heart failure in adults ... patients regardless of New York Heart Association (NYHA) functional class. "Adding FUROSCIX to Orsini's Cardiology Center of ...

A gene therapy for heart failure being developed by Bayer’s AskBio unit has been granted fast-track status by the FDA, shortly after it showed preliminary signs of efficacy in a phase 1 trial.

MitrAssist Lifesciences, a leader in innovative cardiovascular medical devices, today unveiled the initial clinical results of its groundbreaking new product, SIKELIAtm, during the 2024 Transcatheter ...

The benefit was confined to symptoms, but in a very sick population with few options, that’s important, say researchers.